CoChat

Effect of combination therapy with thyroxine (T4) and 3,5,3′-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study

Nygaard, Birte, Jensen, Ebbe Winther, Kvetny, Jan, Jarløv, Anne, Faber, Jens · 2009 · European Journal of Endocrinology

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Abstract

Background: Treatment of hypothyroidism with 3,5,3′-triiodothyronine (T 3) is controversial. A recent meta-analysis concludes that no evidence is present in favour of using T 3. However, the analysis included a mixture of different patient groups and dose-regimens. Objective: To compare the effect of combination therapy with thyroxine (T 4) and T 3 versus T 4 monotherapy in patients with hypothyroidism on stable T 4 substitution. Study design: Double-blind, randomised cross-over. Fifty micrograms of the usual T 4 dose was replaced with either 20 μg T 3 or 50 μg T 4 for 12 weeks, followed by cross-over for another 12 weeks. The T 4 dose was regulated if needed, intending unaltered serum TSH levels. Evaluation: Tests for quality of life (QOL) and depression (SF-36, Beck Depression Inventory, and SCL-90-R) at baseline and after both treatment periods. Inclusion criteria: Serum TSH between 0.1 and 5.0 mU/l on unaltered T 4 substitution for 6 months. Results: A total of 59 patients (55 women); median age 46 years. When comparing scores of QOL and depression on T 4 monotherapy versus T 4/T 3 combination therapy, significant differences were seen in 7 out of 11 scores, indicating a positive effect related to the combination therapy. Forty-nine percent preferred the combination and 15% monotherapy (P=0.002). Serum TSH remained unaltered between the groups as intended. Conclusion: In a study design, where morning TSH levels were unaltered between groups combination therapy, (treated with T 3 20 μg once daily) was superior to monotherapy by evaluating several QOL, depression and anxiety rating scales as well as patients own preference.

Overview

Integrity signals

Registry

Crossref · 10.1530/eje-09-0542

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

23 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 22 references

Cited by

See all 165

Metadata

Authors
Nygaard, B., Jensen, E. W., Kvetny, J., Jarløv, A., & Faber, J.
Affiliations
University of Copenhagen (DK)
Venue
European Journal of Endocrinology
Published
2009-12
Volume
161
Issue
6
Pages
895-902
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2120786909
Cited by
153
References
23
Citations by year
2026: 2 · 2025: 9 · 2024: 11 · 2023: 8 · 2022: 10 · 2021: 11 · 2020: 14 · 2019: 11 · 2018: 14 · 2017: 9 · 2016: 14 · 2015: 7 · 2014: 9 · 2013: 7 · 2012: 8
FWCI
4.11
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
hypothyroidism, triiodothyronine, thyroxine, combination thyroid hormone therapy, quality of life, depression, anxiety, serum TSH, patient preferences
MeSH terms
Adolescent, Adult, Aged, Depression, Drug Therapy, Combination, Female, Humans, Hypothyroidism, Male, Middle Aged, Quality of Life, Antithyroid Agents, Thyrotropin, Thyroxine, Triiodothyronine, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of combination therapy with thyroxine (T4) and 3,5,3′-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. https://app.cochat.ai/papers/10.1530/eje-09-0542
The paper
Nygaard, B., Jensen, E. W., Kvetny, J., Jarløv, A., & Faber, J. (2009). Effect of combination therapy with thyroxine (T4) and 3,5,3′-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. European Journal of Endocrinology. https://doi.org/10.1530/eje-09-0542

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.